News Sentiment

CRBU sentiment intelligence

Caribou Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.93 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+5.8% over one week, +20.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 5.8% Price confirming higher
Trend fit Trend inactive 20.7% over four weeks
Fair value -31.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 29
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 8
TradingView 4
TradingKey 3
simplywall.st 3
marketscreener.com 2
Seeking Alpha 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 17
Analyst action 6
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Ad-hoc-news.de Direct company coverage

Caribou Biosciences stock holds focus on CRISPR therapies

Caribou Biosciences' stock remains focused on its CRISPR-based cell therapy platform, with investors tracking the company's clinical and financing updates. The company's valuation is tied to clinical readouts and program execution in the gene-editing sector, making it sensitive t

Tone
Positive 62/100
Event
Market update
Published
03 Jul 2026 11:40
Source
Ad-hoc-news.de
The Manila Times Direct company coverage

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Caribou Biosciences announced that its President and CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET. The company is a clinical-stage CRISPR genome-editing biopharmac

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 11:40
Source
The Manila Times
marketscreener.com Direct company coverage

Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Value Benchmark

Caribou Biosciences, Inc. (NasdaqGS: CRBU) has been added to the Russell 2000 Value Benchmark. The company, a clinical-stage CRISPR genome-editing biopharmaceutical firm, focuses on developing transformative therapies for severe diseases, including allogeneic CAR-T cell therapies

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 03:09
Source
marketscreener.com
marketscreener.com Direct company coverage

Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Microcap Value Benchmark Index

Caribou Biosciences, Inc. (NasdaqGS:CRBU) has been added to the Russell Microcap Value Benchmark Index. This inclusion is a significant development for the clinical-stage CRISPR genome-editing biopharmaceutical company, highlighting its growing presence in the financial markets.

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 16:42
Source
marketscreener.com
Finviz Direct company coverage

CRBU - Caribou Biosciences Inc Latest SEC Filings

This article provides the latest SEC filings for Caribou Biosciences Inc. (CRBU), detailing its recent stock performance, key financial metrics, insider and institutional ownership, analyst recommendations, and various valuation ratios. The company's stock closed at $1.77 on June

Tone
Neutral 50/100
Event
Analyst action
Published
29 Jun 2026 10:09
Source
Finviz
www.marketscreener.com Direct company coverage

Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell Microcap Index

Caribou Biosciences, Inc. (NasdaqGS: CRBU) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical firm focusing on CRISPR genome-editing technology to develop therapies for diseases, particularly allogeneic CAR-T cell therapies for hematol

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 05:40
Source
www.marketscreener.com
TradingKey Direct company coverage

Caribou Biosciences Inc (CRBU) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Caribou Biosciences Inc (CRBU), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock has a current price momentum score of 6.46 and is trading between a resista

Tone
Negative 38/100
Event
Market update
Published
27 Jun 2026 05:10
Source
TradingKey
TradingView Direct company coverage

Caribou Biosciences, Inc. Actuals & Estimates (NASDAQ:CRBU)

This article provides an overview of Caribou Biosciences, Inc. (NASDAQ:CRBU) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's financial results, such as recent earnings and revenue, and upcoming earning

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 22:40
Source
TradingView
TradingView Direct company coverage

CRBU Forecast — Price Target — Prediction for 2027

This article provides a forecast for Caribou Biosciences, Inc. (CRBU) stock, detailing analyst price targets, historical performance, and key financial metrics. It includes information on the current stock price, market capitalization, earnings, revenue, and upcoming earnings dat

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 14:10
Source
TradingView
CRISPR Medicine News Direct company coverage

Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses

Caribou Biosciences' CB-011, an allogeneic anti-BCMA CAR-T cell therapy, has shown deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Updated phase 1 data from the CaMMouflage trial, including an encouraging case study, indicat

Tone
Positive 95/100
Event
Market update
Published
19 Jun 2026 11:13
Source
CRISPR Medicine News
Stock Titan Direct company coverage

Caribou Biosciences (NASDAQ: CRBU) holders reject officer exculpation

Caribou Biosciences (CRBU) stockholders convened their annual meeting on June 17, 2026, where they elected three Class II directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the current fiscal year. Notably, shareholders rejected

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 20:10
Source
Stock Titan
TradingKey Direct company coverage

Caribou Biosciences Inc (CRBU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Caribou Biosciences Inc. (CRBU), detailing its revenue by region. As of April 6, the company generated $9.48 million, or 84.94% of its revenue, from the United States, with the remaining 15.06% from the rest of the world. Information

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 16:10
Source
TradingKey
TradingKey Direct company coverage

Caribou Biosciences Inc (CRBU) Institutional Confidence

The article provides an analysis of Caribou Biosciences Inc.'s institutional confidence score, which stands at 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion decreased by 49.07% quarter-over-quarter to

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 07:39
Source
TradingKey
Investing.com Direct company coverage

H.C. Wainwright reiterates Caribou Biosciences stock rating at buy

H.C. Wainwright has reiterated a Buy rating and an $11.00 price target for Caribou Biosciences (NASDAQ:CRBU) following positive updated data from its ANTLER trial. The trial's results for vispa-cel in large B-cell lymphoma patients demonstrated high response rates, supporting the

Tone
Positive 73/100
Event
Analyst action
Published
16 Jun 2026 12:09
Source
Investing.com
Seeking Alpha Direct company coverage

Caribou Biosciences, Inc. (CRBU) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow

Caribou Biosciences, Inc. (CRBU) presented a slideshow at the European Hematology Association (EHA) 2026 Congress. The presentation was published on June 12, 2026, and is available through Seeking Alpha. The company's transcripts team was responsible for the content, indicating a

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 11:38
Source
Seeking Alpha
Investing News Network Direct company coverage

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Caribou Biosciences announced long-term data from its ANTLER phase 1 clinical trial for vispa-cel, an off-the-shelf CAR-T cell therapy, showing durable responses in second-line large B cell lymphoma patients. The data presented at the 2026 European Hematology Association Annual M

Tone
Positive 74/100
Event
Market update
Published
11 Jun 2026 17:09
Source
Investing News Network
Investing.com Australia Direct company coverage

Caribou reports phase 1 data for off-the-shelf CAR-T therapy By Investing.com

Caribou Biosciences Inc. reported positive phase 1 data for CB-011, an off-the-shelf CAR-T cell therapy for multiple myeloma, showing high response rates and minimal residual disease negativity. Despite the promising clinical results, the company's stock has recently declined. Ca

Tone
Positive 64/100
Event
Earnings
Published
11 Jun 2026 12:52
Source
Investing.com Australia
Stock Titan Direct company coverage

Off-the-shelf lymphoma cell therapy shows 82% response in early trial

Caribou Biosciences reported long-term phase 1 data for its off-the-shelf CAR-T vispa-cel in second-line large B cell lymphoma, showing an 82% overall response rate and 67% complete response rate, with a median progression-free survival of 17.1 months in optimized-dose patients.

Tone
Positive 72/100
Event
Market update
Published
11 Jun 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

Caribou Biosciences (CRBU) reports durable phase 1 CAR-T responses in lymphoma and myeloma

Caribou Biosciences announced positive, durable Phase 1 clinical trial data for its CAR-T cell therapies, vispa-cel and CB-011, in lymphoma and multiple myeloma, respectively. Vispa-cel in second-line large B cell lymphoma showed an 82% overall response rate and 17.1-month median

Tone
Positive 76/100
Event
Market update
Published
11 Jun 2026 11:40
Source
Stock Titan
Fierce Biotech Direct company coverage

Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3

Caribou Biosciences has demonstrated that its off-the-shelf CAR-T cell therapy, vispacabtagene regedleucel (vispa-cel), achieved a median progression-free survival of 17.1 months, numerically surpassing existing autologous CAR-T treatments like Breyanzi and Yescarta in lymphoma p

Tone
Positive 64/100
Event
Market update
Published
10 Jun 2026 07:10
Source
Fierce Biotech
Market source Direct company coverage

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that its President and CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35 PM ET. The clinical-stage CRISPR genome-editing biopharmaceutical c

Tone
Positive 61/100
Event
Market update
Published
28 May 2026 09:09
Source
Market source